Benzinga | Nov 10, 2020 09:19AM EST

Jefferies Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $26

Jefferies initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $26.